Healey ALS Platform Trial

Back to Active Studies

Help us determine the safety and efficacy of multiple experimental drugs in a single trial (one drug per participant)

Recruiting patients with ALS

Study Name

PI

Volkan Granit, MD, MSc and Michael Benatar, MD, PhD

Study Type

Interventional (Platform Clinical Trial). Randomized. Placebo-controlled.

Eligible Population

Individuals affected with ALS, onset of weakness in the past 36 months, and breathing function (vital capacity) at least 50% of normal. (Other, study drug-specific, eligibility criteria may also apply.)

Study Purpose/Goals

To evaluate the safety and efficacy of multiple experimental agents compared to shared placebo, under the auspice of a single platform trial

Previous agents evaluated include:
- Regimen A: Zilucoplan
- Regimen B: Verdiperstat
- Regimen C: Bioenergetic nanocatalysis (CNM-Au8-nanocrystaline gold)
- Regimen D: pridopidine
- Regimen E: Trehalose (SLS-005)
- Regimen F: ABBV-CLS-7262
- Regimen G: DNL343
Current agents evaluated include:

Procedures/Participation

Participation:

28 weeks of participation
- Screening: up to 4 weeks
- Double-blind treatment: 24 weeks
Option to continue open label or re-randomize to receive a new experimental agent

Procedures: